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Abstract
Background: Osteosarcoma (OS) is the most common primary bone tumour in children and
young adults. Despite improved prognosis, metastatic or relapsed OS remains largely incurable and
no significant improvement has been observed in the last 20 years. Therefore, the search for
alternative agents in OS is mandatory.
Results: We investigated phospho-ERK 1/2, MCL-1, and phospho-Ezrin/Radixin/Moesin (P-ERM)
as potential therapeutic targets in OS. Activation of these pathways was shown by
immunohistochemistry in about 70% of cases and in all OS cell lines analyzed. Mutational analysis
revealed no activating mutations in KRAS whereas BRAF gene was found to be mutated in 4/30 OS
samples from patients. Based on these results we tested the multi-kinase inhibitor sorafenib (BAY
43-9006) in preclinical models of OS. Sorafenib inhibited OS cell line proliferation, induced
apoptosis and downregulated P-ERK1/2, MCL-1, and P-ERM in a dose-dependent manner. The
dephosphorylation of ERM was not due to ERK inhibition. The downregulation of MCL-1 led to an
increase in apoptosis in OS cell lines. In chick embryo chorioallantoic membranes, OS supernatants
induced angiogenesis, which was blocked by sorafenib and it was also shown that sorafenib reduced
Published: 10 December 2009
Molecular Cancer 2009, 8:118 doi:10.1186/1476-4598-8-118
Received: 14 September 2009
Accepted: 10 December 2009
This article is available from: http://www.molecular-cancer.com/content/8/1/118
© 2009 Pignochino et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
Page 2 of 17
(page number not for citation purposes)
VEGF and MMP2 production. In addition, sorafenib treatment dramatically reduced tumour volume
of OS xenografts and lung metastasis in SCID mice.
Conclusion: In conclusion, ERK1/2, MCL-1 and ERM pathways are shown to be active in OS.
Sorafenib is able to inhibit their signal transduction, both in vitro and in vivo, displaying anti-tumoural
activity, anti-angiogenic effects, and reducing metastatic colony formation in lungs. These data
support the testing of sorafenib as a potential therapeutic option in metastatic or relapsed OS
patients unresponsive to standard treatments.
Background
Osteosarcoma (OS) is the most common primary malig-
nant bone tumour in children and young adults and is
characterized by an aggressive clinical course. Chemother-
apy significantly increased 5-year survival of localized OS
patients to approximately 65% [1]. Pulmonary metas-
tases, central presentation and local non-resectable
relapse cause a fatal outcome in the majority of patients
[2,3]. Both novel chemotherapeutic drugs and radiometa-
bolic therapy based on samarium failed to improve over-
all survival [4]. These dismal results are due to P-
glycoprotein overexpression [5] as well as complex karyo-
types [6], which account for chemoresistance. The search
for alternative agents focused on entirely different mecha-
nisms in OS is therefore mandatory.
The advent of molecular targeted therapies has spurred a
search for pathological activation of receptors tyrosine
kinase (RTKs) via various mechanisms in a number of
malignancies including OS. Among the RTKs KIT, Vascu-
lar endothelial growth factor receptor (VEGFR) -2, -3 and
Platelet derived growth factor (PDGFR)-β have been
found to be involved in OS progression and metastatiza-
tion [7-9].
Two major pathways subsequently activated by RTKs are
the phosphatidylinositol 3-kinase (PI3K)/AKT and the
mitogen-activated protein kinases ERK 1/2.
Recent studies have demonstrated that the cytoskeletal
linker protein, ezrin, a member of the ezrin-radixin-
moesin (ERM) family of protein linkers between the actin
cytoskeleton and plasma membrane, plays an important
role in the metastasis of OS and rhabdomyosarcoma, sug-
gesting that these metastasis-associated molecules could
be potential targets for treatment [10]. Matrix metallopro-
teinases (MMPs) play pivotal roles in tumour invasion
through degradation of basement membranes and extra-
cellular matrices [11,12]. MMP-2 and -9 have been found
to be involved in OS tumourigenesis and pulmonary
metastasization [13,14].
Sorafenib (BAY 43-9006) is an orally active biarylureic
multi-kinase inhibitor originally developed to block the
ERK 1/2 pathway by targeting Raf-kinases, such as RAF-1
and B-RAF, as well as in the presence of an V600E activat-
ing mutation. Off-targets of this drug are other RTKs
involved in tumour progression (FLT-3, KIT, fibroblast
growth factor receptor, FGFR-1, RET) and angiogenesis
(VEGFR-2 and 3, and PDGFR-β) [15]. More recently, it has
been demonstrated that sorafenib induces apoptosis in
human leukemia cells and other human tumour cell lines
through down-regulation of the anti-apoptotic protein
myeloid cell leukemia-1 (MCL-1), a Bcl-2 family member
[16].
Beyond its preclinical anti-tumoural activity, sorafenib
was proven to be effective in 3 different chemorefractory
cancers: kidney, liver and thyroid carcinoma. Sorafenib
significantly prolongs progression-free survival as well as
overall survival of treated patients [17-19].
Several molecular targets of sorafenib seem to be involved
in the pathogenesis or progression of OS. One pioneering
work demonstrated the amplification of Raf-1 in one case
of human OS [20], and the expression of PDGF is associ-
ated with OS progression [21]. In addition, VEGF is over-
expressed in 63% of untreated OS and is predictive of
pulmonary metastasis and poor prognosis [22]. A wide
immunohistochemical study on pediatric solid tumours,
among them 18 cases of OS, demonstrated that KIT is
expressed in the entire case series [7]. Inhibition of the
ERK1/2 pathway, mediated by statin treatment, induced
apoptosis in OS cell lines [23]. MCL-1 is expressed in a
variety of different human sarcoma cell lines, and MCL-1
antisense oligonucleotides combined with low-dose
cyclophosphamide provides a synergistic anti-tumour
effect, and may qualify as a promising strategy to over-
come chemoresistance in human sarcoma [24].
These studies suggest that Sorafenib may be active in OS.
However, before exploiting a clinical trial, it was necessary
to conduct an investigation of the activation of possible
targets of sorafenib in both in vitro and in vivo models.
Thus, we investigated the presence of molecular targets of
sorafenib in OS patient specimens and explored the in
vitro  and  in vivo anti-proliferative effects of this multi-
kinase inhibitor as well as its molecular mechanisms of
action. In addition, we explored the effect of sorafenib on
other pathways potentially involved in progression andMolecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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metastatic dissemination of OS such as the ERM complex,
suggesting a novel sorafenib- targetable molecular path-
way.
Results
P-ERK1/2, MCL-1 and P-ERM are highly expressed in OS
To investigate ERK1/2 pathway activation in OS patients,
the expression of phosphorylated ERK1/2 was analyzed in
an entire OS case series by immunohistochemistry, and
compared with normal adjacent tissues as a control.
Nuclear and cytoplasmatic P-ERK1/2 immunostaining
was detected in 20 out of 30 samples (66.7%) and 9 of
them were strongly positive. Representative examples of
P-ERK1/2 staining are shown in Figure 1. These results,
demonstrate that the ERK1/2 pathways are activated in all
the analyzed histotypes (Table 1).
The normal bone counterpart was consistently negative
for activated ERK1/2.
Next, we analysed expression of the MCL-1 protein by
immunohistochemistry (Figure 1). Results shown in
Table 1 demonstrate that 24 out of 30 (80%) expressed
MCL-1 protein in a granular cytoplasmatic staining (mito-
chondria). Ten out of 24 were strongly positive in more
than 50% tumour cells, whilst non-malignant tissues were
consistently negative.
The whole series was also analyzed to detect the phospho-
rylation of cytoskeletal linkers ERM (Figure 1). Twenty-
one out of 30 specimens (70%) displayed P-ERM (Table
1) in the cytoplasmatic side of the plasma membrane. In
contrast, ERM was not phosphorylated in normal osseous
tissues.
Western blot analysis revealed the expression of P-ERK1/
2, MCL-1 and P-ERM in the 7 OS cell lines examined (data
not shown).
B-RAF mutations are present in OS samples from patients
The hotspot regions of B-RAF were investigated in the
whole series. Exon 15 of B-RAF was mutated in 4 samples
(13.3%), as shown in Table 1. One sample had a single-
base deletion in codon 596 of the conserved "DFG" motif
in the regulatory site. This single base deletion causes a
frame-shift that leads to the reading of Val followed by a
Stop-codon instead of Gly, and consequently the transla-
tion of a truncated form of the protein. A second patient
displayed a H608L substitution which has never been
described before. A third sample had the G615R muta-
tion. The fourth sample had a point mutation in the acti-
vation segment phosphorylation site, causing the
substitution of Ser 602 with Tyr (S602Y). These mutations
were not presenting in the surrounding non-tumoural tis-
sues. No B-RAF exon 11 and K-RAS exon 1 and 2 muta-
tions were found in the whole case series.
Sorafenib has anti-proliferative and pro-apoptototic 
effects on OS cell lines
To investigate the effects of sorafenib on in vitro prolifera-
tion, we exposed 7 different OS cell lines to increasing
doses of the drug for 24, 48 and 72 hours. CellGlo™ assays
demonstrated that sorafenib caused a dose- and time-
dependent cell growth inhibition of all the 7 cell lines
tested. IC50 values after 72 hours of treatment were calcu-
lated on the basis of these results and are shown in Table
2. At this time point, DNA content and apoptosis analysis
was evaluated by FACS. Sorafenib did not induce cell cycle
arrest, but a dose dependent increase of the percentage of
cells in sub-G0 phase considered to be apoptotic cells (Fig-
ure 2, panel A). Further Annexin V/PI staining confirmed
that sorafenib induced a dose-dependent increase in the
percentage of apoptotic cells, as shown in Figure 2, panel
B. In addition, sorafenib displayed a dose-dependent
inhibition of anchorage-independent cell growth, as
shown by soft agar assays (Figure 2, panel C).
Sorafenib down-regulates P-ERK 1/2, MCL-1 and P-ERM 
expression in OS cell lines
To elucidate the mechanisms of cell growth inhibition
and apoptosis induced by sorafenib, OS cells were
exposed to the drug at concentrations ranging from 0 to
20 μM for 24 hours. Results demonstrated that sorafenib
induced a dose-dependent decrease in phosphorylated
ERK1/2 and ERM in all the 7 cell lines tested. Representa-
tive western blots are shown in Figure 3 (panel A and C).
Expression of total ERK and ERM was not affected by sor-
afenib treatment.
To verify whether ERM phosphorylation is dependent on
PDGFR or KIT pathways, OS cell lines were treated with
imatinib mesylate (STI571, Gleevec) a known inhibitor of
PDGFR and KIT as well as ABL. As shown in Figure 3
(panel D) STI571 treatment did not affect ERM phospho-
rylation.
In addition, the effect of sorafenib on phosphorylation of
ERM is not ERK dependent. Indeed, the inhibition of ERK
pathway resulting from treatment with UO126, a MEK-
specific inhibitor, did not affect phosphorylation of ERM
(Figure 3, panel D).
The expression of MCL-1 in OS cells treated with soraf-
enib for 24 hours was analyzed by immunoblotting. A sig-
nificant dose-dependent reduction of MCL-1 protein was
detected (Figure 3, panel B).
Inhibition of MCL-1 expression induces apoptosis in OS 
cell lines
In order to investigate if the anti-apoptotic effect of soraf-
enib could be attributable to the inhibition of MCL-1 we
exploited siRNA technology. SiRNA MCL-1 transfection
significantly decreased MCL-1 protein expression in allMolecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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Table 1: Characteristics of OS case series.
Case Gender Histology Grade Site BRAF mutations P-ERK1/2 * MCL-1 * P-ERM *
1 M OSTEOBLASTIC G4 TIBIA - - + +
2 M OSTEOBLASTIC G4 FEMUR - - + -
3 F OSTEOBLASTIC G4 FEMUR - - - -
4 M OSTEOBLASTIC G4 TIBIA - - - +
5 M OSTEOBLASTIC G4 HOMER 596 delA - - -
6 F OSTEOBLASTIC G4 TIBIA - - + -
7 F OSTEOBLASTIC G4 FEMUR - - + +
8 M OSTEOBLASTIC G4 FEMUR - - ++ +
9 M OSTEOBLASTIC G4 TIBIA - - + +
10 M OSTEOBLASTIC G4 FEMUR - - + +
11 M OSTEOBLASTIC G4 FEMUR - ++ ++ +
12 F OSTEOBLASTIC G4 FEMUR - + - -
13 M OSTEOBLASTIC G4 FEMUR H608L ++ ++ +
14 M OSTEOBLASTIC G4 FEMUR - + + -
15 M OSTEOBLASTIC G4 HOMER - ++ ++ +
16 M OSTEOBLASTIC G4 TIBIA - ++ + +
17 F OSTEOBLASTIC G4 FEMUR - + + +
18 M OSTEOBLASTIC G4 FEMUR - + ++ -
19 F OSTEOBLASTIC G4 HOMER - ++ + ++
20 M OSTEOBLASTIC G4 TIBIA - + + +
21 M OSTEOBLASTIC G4 FEMUR - ++ ++ +
22 M OSTEOBLASTIC G4 FEMUR G615R ++ ++ ++
23 M FIBROBLASTIC G4 TIBIA - + ++ -
24 M FIBROBLASTIC G4 FEMUR - ++ - +
25 M OSTEOBLASTIC G4 FEMUR - + + -
26 F OSTEOBLASTIC G3 HOMER - + - +
27 M OSTEOBLASTIC G4 FEMUR - + + ++Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
Page 5 of 17
(page number not for citation purposes)
the 7 cell lines tested. Different OS cell lines displayed dif-
ferent sensitivity to MCL-1 silencing. Namely, in MG63
cells, which were the most sensitive to MCL-1 silencing,
there was a strong reduction in MCL-1 protein expression,
as demonstrated by western blot analysis (Figure 4, panel
A). Meanwhile, in SAOS-2 cells, the least sensitive to MCL-
1 silencing, only a minor down-regulation of MCL-1 pro-
tein was observed (Figure 4 panel A). SiRNA-induced
MCL-1 down-regulation produced an increase of apop-
totic OS cells compared to cells transfected with control
siRNAs (Figure 4, panel B). The percentage of late apop-
totic cells was higher in MG63 cells than in SAOS-2 cells
(44.2% vs 16.0% respectively), reflecting the level of
MCL-1 down-regulation.
Sorafenib inhibits MMP2 and VEGF production in OS cell 
lines
To explore the activity of sorafenib on the effectors
involved in tumour progression and angiogenesis, we
measured MMP2 and VEGF production in supernatants of
all the 7 cell lines tested. We observed that different cell
lines exhibit different basal level of MMP2 and VEGF-A,
28 M OSTEOBLASTIC G4 FEMUR S602Y + + +
29 F OSTEOBLASTIC G4 HOMER - + ++ +
30 M OSTEOBLASTIC G4 TIBIA - ++ ++ ++
Gender, histological subtypes, grading, site of tumor origin, immunohistochemical results of P-ERK1/2, MCL- 1 and P-ERM expression and BRAF 
exon 15 mutations of each osteosarcoma samples from patients. intensity of expression: (-)< 10% positive cells scored -, 10-50% positive cells 
scored +;> 50% positive cells and high staining intensity scored ++).
Table 1: Characteristics of OS case series. (Continued)
Representative immunostaining of osteosarcoma samples Figure 1
Representative immunostaining of osteosarcoma samples. Negative (-), positive (+) and strongly positive (++) samples 
for P-ERK1/2, MCL-1 and P-ERM expression.Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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being higher in MG63 cells, and lower in HOS cells (Fig-
ure 5). Treatment with sorafenib produced a consistent
reduction of the concentration of MMP2 and VEGF-A in
all cell lines tested (Figure 5). However, the magnitude of
this reduction was heterogeneous. Namely, after 48 hours
MMP2 produced by 106 cells was reduced to 47.8% in
KHOS, 64.8% in HOS, 63.9% in U2-OS, 40.7% in SAOS-
2, 59.6% in SJSA-1; 86.5% in MG63; and 54.4% in
MNNG-HOS cells.
Sorafenib treatment led to the reduction of VEGF-A pro-
duced by 106 cells to 57.7% in KHOS, 73.1% in HOS,
80.5% in U2-OS, 52.9% in SAOS-2, 67.5% in SJSA-1;
47.1% in MG63; and 65.7% in MNNG-HOS cells.
Sorafenib has an anti-angiogenic effect in CAM
Chick chorioallantoic membrane assay was performed to
investigate the angiogenic potential of OS cell lines and
the anti-angiogenic effect of sorafenib in vivo.
The supernatant of U2OS cells clearly increased sprouting
angiogenesis in CAM (Figure 6, panel B) compared with
culture medium alone (Figure 6, panel A), indicating the
secretion of angiogenic factors by OS cells. Anti-ang-
iogenic effects of sorafenib were tested by two different
approaches, i.e. treating the cells prior to CAM stimula-
tion or directly adding sorafenib into the CAM already
stimulated with untreated tumour cell supernatant. When
U2OS were treated with low concentration of sorafenib to
avoid cell mortality,, the supernatant developed a lower
angiogenic response than untreated cells (Figure 6, panel
C), probably due to the decrease of secreted angiogenic
factors. The treatment of CAM with sorafenib blocked
angiogenesis induced by U2OS cell supernatant, suggest-
ing that the drug may also act on host vasculature (Figure
6, panel D).
Sorafenib displays anti-tumoural activity in vivo against 
human OS xenografts
Based on their median level of MMP2 and VEGF-A pro-
duction, and their previously demonstrated tumouri-
genicity in mice [14], U2OS and SJSA-1 cell lines were
chosen for in vivo studies. Sorafenib treatment dramati-
cally reduced tumour volume of s.c. U2OS xenografts in
SCID mice compared to untreated mice as shown in Fig-
ure 7 (Panel A). Moreover, the number of patented blood
vessels was strikingly reduced in tumours of treated mice,
as shown in Masson trichromic stained sections (Figure 7,
panel B).
Histological analysis revealed that sorafenib-treated
xenografts had a lower tumour cell number, which mostly
showed marked regressive nuclear changes as pyknosis
(Figure 8, panels A-B). In treated mice, OS viable cells
were present on the edge of the lesion showing a general-
ized shrinkage of the viable tissue thickness. A sharp
increase in the extracellular matrix is evident in histologi-
cal sections from sorafenib-treated mice compared to
non-treated mice (Figure 8, panel C-D).
Sorafenib reduces metastasis formation in lungs
One million SJSA-1 cells were injected into the tail vein of
SCID mice giving rise to pulmonary colonies within 3
weeks. Subsequent treatment with sorafenib for 16 days
inhibited tumour colony growth. In some of the treated
mice with the highest sorafenib dosage, a massive lung
collapse with pulmonary bleeding was observed at
autopsy. The percentage of area occupied by lung foci ana-
lyzed per optical field after hematoxylin and eosin stain-
ing at lower magnification (40×) was 73% ± 14, 84% ±
11,40% and 35% ± 7 in sorafenib 10, 30, 100 mg/kg/day
treated mice respectively. In Figure 8, panels E-F, repre-
sentative sections of lung from untreated- and sorafenib-
treated mice are shown.
Sorafenib down-regulates P-ERK 1/2, MCL-1 and P-ERM 
expression on OS xenografts
Molecular targets of sorafenib were also evaluated in
xenograft sections. Immunohistochemical analysis clearly
demonstrated the reduced phosphorylation of ERK1/2,
with the percentage of positive cells diminishing from
84% (score ++) in sections of untreated xenografts to
15%, 30% (score +) and 6% (score -) in 10, 30 e 100 mg/
kg/die sorafenib treated mice respectively (p < 0.05).
Expression of MCL-1 is also slightly down-regulated fol-
lowing sorafenib treatment. MCL-1 was expressed in 90%
cells (scored ++) of untreated xenografts and in 75% (++),
60% (++) and 40% (+) in 10, 30 and 100 mg/kg/die sor-
afenib-treated mice respectively (p < 0.05). P-ERM is
Table 2: Concentrations of sorafenib inhibiting 50% of OS cell 
line proliferation.
Cell line IC50 (μM) Confidence Intervals (μM)
MG63 2.793 2.32-3.35
U2OS 4.677 2.99-6.61
SAOS-2 3.943 1.87-5.31
KHOS 2.417 1.88-3.10
HOS 4.784 3.99-5.48
SJSA-1 4.511 3.01-6.71
MNNG-HOS 4.814 3.13-6.39
IC50 values (μM) and relative 95% confidence intervals obtained after 
72 hours of sorafenib exposure.* IC50: Sorafenib concentration 
inhibiting 50% of the cell line proliferation.Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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Sorafenib induces apoptosis and inhibits anchorage independent cell growth of a representative OS cell line Figure 2
Sorafenib induces apoptosis and inhibits anchorage independent cell growth of a representative OS cell line. 
DNA content (A) and apoptosis (B) analysis after 72 h treatments. Soft agar assays as described in "materials and methods" 
section (C).Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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strongly expressed along the inner layer of the plasma
membrane in a continuous fashion in 50% of viable cells
in untreated mice (scored ++). Instead, sections from
treated xenografts displayed a weak P-ERM staining in a
discontinuous fashion (scored +).
Discussion
It is well known that ERK 1/2 play a key role in different
neoplasia. Moreover, even in cancer like GISTs driven by
other kinases, activation of KIT or PDGFR-α lead to phos-
phorylation of ERK 1/2 [25] and these kinases mediate the
proliferative advantage of the neoplastic cells. Imatinib
blocks KIT signalling, causing the proliferative arrest of
gastrointestinal stromal tumours (GISTs), and the inacti-
vation of ERK 1/2. However, resistance to imatinib is
accompanied by reactivation (phosphorylation) of ERK
1/2. Among the new drugs with specific molecular targets
sorafenib was shown to be effective in renal cell carci-
noma and hepatocarcinoma, I through the inhibition of
ERK1/2 pathway [17,18]. These results, along with the
unsatisfactory outcome of relapsed and metastatic OS
cases led us to investigate the presence and role of soraf-
enib targets in paraffin-embedded tissue from OS patients
as well as in several OS cell lines and, thereafter, to explore
sorafenib activity in xenograft models of human OS.
We demonstrated that 66.6% of OS samples from patients
displayed an activated ERK 1/2 pathway suggesting that it
may be relevant in increased OS proliferation. There was
only one prior datum [26] addressing the overexpression
of ERK 1/2 in OS. We observed a highly reproducible and
consistent expression of P-ERK1/2 among OS specimens.
Furthermore, activated ERK 1/2 were only present in the
neoplastic tissue and not in the normal tissue surrounding
the tumour. Its selective expression is a clue to a prolifer-
ative role compared to normal tissue.
Another metabolic pathway often involved in tumour
growth advantage regards the mechanisms preventing
apoptosis. Among sorafenib off-targets, we investigated
and found the antiapoptotic protein MCL-1 activated in
84% of OS specimens, emphasizing its role as a possible
mechanism of survival after chemotherapy. This result is
intriguing as it may represent both a reason to test soraf-
enib activity independently from ERK 1/2 expression and
a possible future target itself in OS.
Mutational status of the target is critical to the effective
inhibition by small inhibitors in at least two cancers: non
small cell lung cancers [27] and GIST [25]. Constitutive
ERK activation is common in human cancers and is often
the result of activating mutations of B-RAF and K-RAS. A
B-RAF mutation occur in approximately 8% of human
tumours (melanoma, papillary thyroid cancer and colon
cancer) and in over 80% of cases it is represented by a sin-
gle base-pair substitution in exon 15 at codon 600
(V600E) [28]. Therefore, we evaluated the presence of B-
RAF mutations in our series. We demonstrated B-RAF
mutations in 13.3% of cases: three mutations have already
been described, whilst H608L is a novel point mutation of
unknown functional significance. On the contrary, we
could not detect any mutations in B-RAF exon 11 or in K-
RAS exon 1 and 2. Since sorafenib is active in wild type B-
RAF, and mutated forms represent only a minority, this
finding does not stand against its clinical application in
OS.
Ezrin was recently pointed out as one of the major deter-
minants of metastatic behaviour in OS [29]. We investi-
gated the expression of active ERM complexes (the
phosphorylated form) in order to show if the ezrin path-
Sorafenib induced down-regulation of P-ERK 1/2 (A), MCL-1  (B) and P-ERM (C) on U2OS Figure 3
Sorafenib induces down-regulation of P-ERK 1/2 (A), 
MCL-1 (B) and P-ERM (C) on U2OS. Effect on P-ERM is 
independent from PDGFR, C-KIT and ERK pathways (D). 
Cells were cultured for 24 hours with escalating doses (5, 10, 
20 μM) of sorafenib, 10 μM STI571, 10 μM UO126 or left 
untreated. After protein extraction P-ERK 1/2 (A), MCL-1, 
(B), P-ERM (C and D) immunoblotting was carried out.Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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way was active in the OS case series examined. Interest-
ingly, for the first time, we showed ERM activation in 70%
of cases and in all the OS cell lines tested.
Our data strengthen the role of ezrin in OS and the need
to further explore the targeting of ezrin in this neoplasia.
In vitro preclinical models of human OS cell lines allowed
us to test sorafenib activity. All the 7 cell lines we studied
clearly showed that sorafenib inhibits OS cell growth. This
event is not due to cell cycle arrest but to the induction of
apoptosis, probably via a mechanism involving the MCL-
1 downregulation, as already demonstrated in acute mye-
loid leukemia [16]. Indeed, MCL-1 silencing with specific
siRNA induced an increase of apoptotic cells in OS in vitro
models.
Furthermore, sorafenib activity in OS could be mediated
by P-ERK 1/2 and P-ERM downregulation involved in pro-
liferation and metastasization respectively [15,29].
Since the UO126-induced inhibition of the ERK pathway
does not affect ERM phosphorylation we can affirm that
sorafenib is able to down-regulate signalling through ERM
MCL-1 down-regulation induces apoptosis in OS cell lines Figure 4
MCL-1 down-regulation induces apoptosis in OS cell lines. MCL-1 protein expression (A) and annexin V/PI staining (B) 
in MG63 and SAOS-2 after MCL-1 silencing with siRNA.Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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in an ERK-independent manner. This effect is also
PDGFR-independent. Indeed, treatment of OS cell lines
with STI571 does not change the phosphorylation status
of ERM. Our findings unveiled the ERM pathway to be a
novel molecular target of sorafenib, and prompted us to
further investigate this molecular mechanism of action.
Matrix metalloproteinases are one of the main causes of
the invasive phenotype of tumour cells. It is noteworthy
that MMP2 (gelatinase A) has been implicated in invasion
and metastasis in several cancers [10,11]. We demon-
strated that sorafenib is able to inhibit MMP 2 production
by OS cell lines, consistent with ERK1/2 involvement in
the induction of MMPs [30,31]. Furthermore, the reduc-
tion of MMP2 production may determine a diminished
invasiveness potential of OS. This finding is an intriguing
aspect of sorafenib use in the clinical setting of OS.
VEGF, the principal stimulator of angiogenesis, is also
involved in the metastatic behaviour of OS [9]. We
showed sorafenib induces a consistent reduction of VEGF
production in OS cell lines, most likely due to ERK1/2
inhibition. Indeed, VEGF mRNA was blocked by the
ERK1/2 pathway inhibition [32].
Therefore, the anti-tumoural activity of sorafenib in OS
may also be caused by inhibition of the blood supply due
to the reduction of new blood vessel formation, as
observed in CAM assays, confirming its antiangiogenic
activity.
A xenograft OS model allowed us to verify whether soraf-
enib would modify the growth of OS cell lines in vivo. Our
results clearly show sorafenib had a major impact on this
endpoint. OS cell lines inoculated in SCID mice grow at a
very high rate, causing death of the recipients in a short
time. Sorafenib strongly reduced tumour dimensions after
16 days of treatment even at a lower dosage (10 mg/Kg/
die). Two aspects must be stressed: sorafenib treatment
began with established masses, just as in human OS
relapses where tumours are also often dimensionally con-
spicuous. Secondly, we observed significant tumour
shrinkage after a relatively short course of therapy. This is
expected to be the usual response to chemotherapy drugs,
but not necessarily to small inhibitors as TK inhibitors
may be efficient in prolonging survival without any signif-
icant tumour shrinkage [33]. Dimensional tumour
response might imply a major antitumour effect of this
drug in OS. Finally, lungs are by far the most frequent
metastatic site in OS. In our xenograft model, Sorafenib
was shown to reduce mouse death rate and we demon-
strated a reduction in the dimension and number of lung
nodules. On OS xenografts, immunohistochemistry anal-
ysis revealed that ERK1/2, MCL-1 and ERM were consist-
ently inhibited, confirming the sorafenib-induced
mechanisms of action. As in renal cell carcinoma and in
hepatocarcinoma, the antiangiogenic properties of soraf-
enib may play a major role in its anti-tumoural effect in
OS as well. However, elevated VEGF production is not a
requirement for sorafenib activity in OS, since sorafenib
was also effective in the SJSA-1 xenografts which produce
lower levels of VEGF compared to other OS cell lines.
Conclusion
Due to the discouraging results of present therapies in
relapsed OS, our work was primarily focused on searching
for molecular cues useful for new therapeutic approaches
as target therapies. We identified a consistent expression
of activated ERK1/2, MCL-1 in a homogeneous OS case
series. These molecular players represent suitable targets
of sorafenib. In particular, sorafenib caused in vitro and in
vivo  down-regulation of MCL-1 and inhibition of the
ERK1/2 pathway. For the first time, we demonstrated that
ELISA test for MMP2 and VEGF quantification on osteosar- coma cell line supernatants Figure 5
ELISA test for MMP2 and VEGF quantification on 
osteosarcoma cell line supernatants. The concentration 
of secreted MMP2 (a) and VEGF (B) on 48 h conditioned 
supernatants of untreated (Black bars) and 5 μM sorafenib 
treated (white bars) OS cells was shown per 106 cells as 
Mean +/- standard deviation (Y error bars) of 2 different 
experiments in triplicate. a, p < 0.05 versus untreated cells; b, 
p < 0.05 versus sorafenib.Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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Sorafenib inhibits angiogenesis in CAM mode Figure 6
Sorafenib inhibits angiogenesis in CAM mode. A. Culture medium (n = 4). A1: 10× magnification, A2: 20× magnification; 
B. Osteosarcoma cell line conditioned medium (n = 6). B1:10× magnification, B2: 20× magnification; C. Conditioned medium of 
sorafenib treated cells (n = 5). C1:10× magnification, C2: 20× magnification; D. Osteosarcoma conditioned medium plus soraf-
enib 1 μM (n = 7). D1:10× magnification, D2: 20× magnification.Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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ERM, a well known marker of tumour progression and
metastasis, was largely expressed in OS specimens, and
that sorafenib inhibited its phosphorylation in in vitro and
in vivo models. Lastly, we demonstrated an in vitro pro-
apoptotic effect of sorafenib and an anti-tumour activity
in OS xenograft in murine models. We believe these data
support an investigation of sorafenib activity in a phase II
study in relapsed or unresectable metastatic patients
affected by OS following the failure of conventional ther-
apies.
Methods
OS specimens and cell lines
A homogeneous case series (Table 1) of formalin-fixed
paraffin-embedded samples of 27 osteoblastic osteosar-
coma grade G4, 1 osteoblastic osteosarcoma grade G3 and
2 fibroblastic osteosarcoma grade G4 were collected at the
Istituti Ortopedici Rizzoli, Bologna, Italy.
Seven osteosarcoma cell lines (SJSA-1, U2OS, SAOS2,
MG63, HOS, MNNG/HOS and KHOS) were purchased
from American Type Culture Collection (Manassas, VA,
USA). All cells were cultured in RPMI 1640, (Invitrogen,
Paisley, UK) in the presence of 10% heat inactivated fetal
calf serum (FCS), 1% L-glutamine, and penicillin/strepto-
mycin (10,000 U/ml and 10,000 g/ml, respectively), with
medium changes every 2 to 3 days.
Immunohistochemistry
The expression of phospho-ERK1/2 (P-ERK1,2), MCL-1
and P-ERM proteins was performed on paraffin-embed-
ded tumour sections (5 μm) mounted onto ChemMate
Capillary Gap Microscope slides (Dako Cytomation,
Milan, Italy), dried in a 45°C oven for 12 hours, deparaffi-
nized in xylene, and rehydrated in graded alcohols and
distilled water. Sections were heated in 10 mM citrate
buffer pH 6.0 in a water bath at 96°C for 45 minutes,
cooled, and stored in TBS at pH 7.6. Endogenous peroxi-
dase activity was blocked with 0.3% hydrogen peroxide
for 10 minutes, followed by treatment with V-block (Lab
Vision Corporation, Fremont, CA, USA) for 30 minutes.
Sections were incubated overnight in a moist chamber at
4°C with the primary antibodies anti MCL-1 (MAB4602
dilution 1:100 Chemicon-Millipore, Temecula, CA), anti
P-ERK1/2 and anti P-ERM (20G11 and 41A3 dilution
1:100 Cell Signaling Technologies, Danvers, MA, USA).
After washing in TBS-Tween, sections were incubated with
secondary antibody and horseradish peroxidase conju-
gated with polymer for 30 minutes. Staining was visual-
ized using 3-3'diaminobenzidine (Envision+ Dual Link
System-HRP, Dako Carpinteria, CA, USA) for 5 minutes,
counterstained with Mayer's hematoxylin (Sigma Chemi-
cals, St. Louis, MO, USA) for 1 minute, dehydrated in a
series of graded ethanol, cleared in xylene and mounted.
Eureka imaging technology was used to analyze 1000 cells
per sample. Staining intensity as well as the percentage of
maximally stained tumour cells in each core biopsy were
recorded (< 10% positive cells scored -, 10-50% positive
cells scored +; > 50% positive cells and high staining
intensity scored ++).
Mutational analysis
Genomic DNA was extracted from deparaffinized samples
and cell lines, with the use of the QIAamp DNA Mini Kit
(Qiagen, Milan, Italy) following the manufacturer's
instructions. To search more frequent mutated sites, exon
1 (forward primer: GAATGGTCCTGCACCAGTAA; reverse
primer: GTGTGACATGTTCTAATATAGTCA) and exon 2
(forward primer: GGTGGAGTATTTGATAGTGTATTAACC
reverse primer AGAATGGTCCTGCACCAGTAA) of K-RAS,
exon 11 (forward primer TCCCTCTCAGGCATAAGGTAA;
Sorafenib activity in OS xenograft models Figure 7
Sorafenib activity in OS xenograft models. In three dif-
ferent experiments, one group of mice was injected s.c. into 
the right flank with U20S and one group of mice was injected 
e.v. with SJSA-1 cells. Five mice per group were orally 
treated daily with sorafenib (0-10-30-100 mg/kg/die) for 16 
days as described in the Materials and Methods section. (A) 
Sorafenib reduces tumour volume OS xenografts in SCID 
mice. The graph indicates the mean tumour volume (mm3) 
measured using calipers at 0, 7 and 16 days of sorafenib 
treatment (Error bars: standard deviation). (B) Sorafenib 
reduces blood vessel number. The graph shows the mean 
number of patented blood vessel +/- standard deviation cal-
culated in 10 fields at 40× magnification on Masson's trichro-
mic staining.Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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Sorafenib reduces tumour mass in OS xenografts in SCID mice Figure 8
Sorafenib reduces tumour mass in OS xenografts in SCID mice. Histological sections derived from sorafenib 
untreated (a) and treated (b) xenografts stained with Hematoxylin and Eosin show massive necrosis and reduced cellularity. 
Sorafenib reduces blood vessel number. 40× magnification on Masson's trichromic staining of sorafenib untreated (c) and 
treated (d) xenografts. Sorafenib reduces lung OS foci. Pictures show representative examples (10× magnification) of OS foci in 
lung sections of untreated (e) and sorafenib-treated mice (f).Molecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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reverse primer: ATCAAAGGAAATATTCACTGTTCG) and
exon 15 (forward primer: TGCTTGCTCTGATAG-
GAAAATG; reverse primer: AGCATCTCAG-
GGCCAAAAAT) of B-RAF were amplified by PCR.
PCR products were then purified using QIAquick PCR
purification kit (Qiagen Milan, Italy) and sense and anti-
sense sequences were obtained by using forward and
reverse internal primers respectively. Each exon was
sequenced using the BigDye Terminator Cycle sequence
following the PE Applied Biosystem strategy and Applied
Biosystems ABI PRISM3100 DNA Sequencer (Applied
Biosystem, Forster City, CA, USA). All mutations were
confirmed performing two independent PCR amplifica-
tions and their somatic origin was demonstrated, exclud-
ing the presence of the same mutation in the surrounding
normal tissue.
Drugs and reagents
Sorafenib (BAY-9006), provided by Bayer Pharmaceuti-
cals Corporation, West Haven, CT, USA, was dissolved in
Polyethylene Glycol 400 (PEG-400 Sigma-Aldrich, St.
Louis, MO, USA) at a final concentration of 10 mM, and
stored at -20°. The drug was diluted in RPMI 1640, (Inv-
itrogen, Paisley, UK) to the desired concentration for in
vitro studies. Vehicle was added to cultures as a solvent
control. For in vivo experiments sorafenib tosylate was pre-
pared fresh every day dissolving it in Cremophor EL
(Sigma-Aldrich, St. Louis, MO, USA)/95% ethanol
(50:50) following 20 minutes sonication. MEK-specific
inhibitor UO126 (Promega Corporation, Madison, WI,
USA) was prepared at an initial concentration of 10 mM
in DMSO, stored at -80°C and used at a final concentra-
tion of 10 μM within 7 days. STI571 (purchased from
Sequoia Research Products, Pangbourne UK) was stored
in a 10 mM stock solution in dimethyl sulfoxide (DMSO)
at -80°C.
Cell growth assay
Cell viability was determined with Cell Titer-Glo® lumi-
nescent cell viability kit (Promega Corporation, Madison,
WI, USA) on OS cell lines after treatment with escalating
doses of sorafenib (from 2.5 to 10 μM) at different time
points (from 24 to 72 hours). This method is based on the
mesurement of ATP production by cells, proportional to
the number of viable cells, detected by luciferin-luciferase
reaction. The luminescent signal developed was measured
at 560 nm by DTX880 spectrofluorimeter multimode
detection microplate reader (Beckam Coulter, Fullerton,
CA, USA).
The IC50 value (concentration inhibiting 50% of the cell
growth compared with PEG-400 control) and the relative
confidential range were calculated for each cell line after
72 hours of sorafenib treatment using GraphPad Prism
software version 5.0.
DNA content analysis and detection of apoptosis
Following trypsinization, harvested cells were washed
with chilled PBS. Cells were then fixed with 4 ml of chilled
70% ethanol and stored at -20°C. Following washing
with chilled PBS, cells were pelleted and resuspended in
500 μl of PBS containing propidium iodide (PI, Sigma,
0.06  μg/ml) and RNase T1 (Roche, 1000 U/ml). Flow
Cytometry was performed with FACS calibur employing
the Cell Quest software. Cells with DNA content less than
that of G0/G1-phase cells were considered to be apoptotic
(sub-G0). Apoptosis was measured using the ApoAlert
Annexin V-APC kit (Bender MedSystems Inc. Burlingame,
CA). Cells were seeded in appropriate cell culture condi-
tions in 60 mm plates. The following day, medium was
replaced with fresh medium containing 10% FBS and the
appropriate concentration of sorafenib. After 72 hours of
incubation at 37°C, both adherent and non-adherent
cells were harvested, washed once with cold PBS (0.15
mol/L, pH 7.2) and twice with binding buffer (150 mM
NaCl2, 10 mM CaCl2, 10 mM Hepes). Cells were centri-
fuged at 3000 rpm for 5 min and resuspended in 1× bind-
ing buffer at a density of 1.0 × 106 cells per mL; 100 μL of
the resuspended cells were incubated with APC conju-
gated annexin V and PI (0.5 μg/ml) for 15 min at RT in the
dark. One hundred μL of 1 × binding buffer were added to
the samples and the analysis was performed by FACS
using Cell Quest Research Software (Becton Dickinson)
and winMDI.2.8.
Soft agar assay
Two thousand cells in 0.5 ml of 0.5% SeaPlaque Agarose
low melting temperature (Lonza Rockland, ME, USA)
with RPMI supplemented with 20% FBS and scalar con-
centrations of sorafenib were plated onto the top of the
existing 1% bottom noble agar in each well of 24-well tis-
sue culture plates. Plates were incubated at 37°C in a
humidified atmosphere with 10% CO2 for three weeks.
Medium was replaced with fresh medium and drug every
3 days. At the end of 3 weeks, colonies were stained with
0.05% crystal violet solution.
CAM (chick chorioallantoic membrane) assay
Fertilized chicken embryos were incubated for 3 days at
37°C at 70% humidity. A small hole was made over the
air sac at the end of the egg and a second hole was made
directly over the embryonic blood vessels. After 7 days,
cortisone acetate-treated filter disks (5 mm) were satu-
rated with a) culture medium with 0,5% FBS; b) superna-
tant of 106 U2OS cells harvested after 72 h, c) same as b)
plus 1 μM sorafenib and d) supernatant of U2OS cells
treated for 72 h with 1 μM sorafenib. After 3 days CAMs
were fixed with 4% parafolmaldehyde for 10 min at roomMolecular Cancer 2009, 8:118 http://www.molecular-cancer.com/content/8/1/118
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temperature, filter disks were excised and pictures were
taken with a QIcam FAST1394 digital color camera (QIm-
aging) connected to the stereomicroscope (model SZX9;
Olympus).
Western Blot analysis
Five to ten million cells were washed with 1× PBS and
lysed with lysis buffer (50 mM TrisHCl pH 7.5, 250 mM
NaCl, 2 mM EDTA, 50 mM NaF, 0.1 mM Na3VO4, 0.5%
Nonidet-P40, 1 mM DTT) and a cocktail of protease
inhibitors (Sigma-Aldrich) for 15 minutes at 4°C and cen-
trifuged at 14000 rpm for 15 minutes. The protein con-
centration of cell lysates was measured using the Bio-Rad
DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA,
USA) and 20 μg of proteins were resolved on 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and electrotransferred to 0.45 μm PVDF (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA) at 180 mA
for 90 minutes at 4°C. Nonspecific sites were blocked by
incubating for 1 hour with 5% non fat dry milk (Bio-Rad
Laboratories, Hercules, CA, USA) in 1× Tris-buffered
saline-Tween (TBST) (20 mM Tris-HCl pH 7.5, 500 mM
NaCl, 0.1% Tween-20). Membranes were first incubated
overnight with primary antibody and then with 1 μg/ml
horseradish peroxidase conjugated secondary antibody
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) in
1× TBST with 1% non-fat dry milk. The anti-ERK1/2, P-
ERK1/2 and MCL-1, P-ERM, ERM and β-actin were pur-
chased from Cell signaling (Cell Signaling Technologies,
Danvers, MA, USA). After each incubation step, mem-
branes were washed 3 times for 15 minutes with 1× TBST,
and revealed with a chemiluminescence reagent (Lumi-
GLO, Cell Signaling Technologies, Danvers, MA, USA)
and exposed to autoradiography film.
ELISA assays
Sub-confluent OS cell lines were treated with sorafenib (5
μM) or PEG-400. The conditioned medium was collected
48 hours later, cleared by centrifugation at 14,000 rpm
(4°C) for 5 minutes for ELISA analysis using Quantikine
kits (R&D Systems, Minneapolis, MN) following manu-
facturer's instructions to quantify the amount of VEGF
and metalloproteinase production. Cells were detached
with trypsin and counted. All experiments were per-
formed three times in triplicate and the mean and stand-
ard deviations were calculated. Results were done after
normalization based on cell number.
MCL-1 silencing
Validated small interfering RNAs (siRNA) targeting MCL-
1 (SI02781205) and appropriate non-silencing control
(AllStars Negative Control siRNA, 1027280) were synthe-
sized by Qiagen. RNAi liposomes were generated using
HyperFect Transfection Reagent (Qiagen) complexed with
siRNA (final concentration 5 nM) in RPMI following the
appropriate protocol. Samples were analyzed using West-
ern Blot and FACS analysis at various time-points.
Mice Xenograft models
CB.17 severe combined immunodeficient (SCID) female
mice (5-6 weeks old; purchased from Charles Rivers
(Lecco, Italy) were used for in vivo experiments. Animals
were maintained at the animal facilities of CIOS (Torino,
Italy) and handled according to institutional regulations,
under sterile conditions in cage micro isolators. In three
different experiments, one group of mice was injected
subcutaneously (s.c.) into the right flank with 2.5 × 106
U20S in 50% growth factor-reduced BD Matrigel base-
ment membrane matrix (BD Biosciences, San Jose, CA),
and one group was injected intravenously (i.v.) with 105
SJSA-1. When the right flank xenografts were established
at about 500 mm3 and after 3 weeks for i.v. injected mice,
the animals (5 mice per group) were treated daily with
either sorafenib (10-30-100 mg/kg/die) or vehicle by oral
gavage for 16 days and then sacrificed. S.c. xenograft
diameters were measured every 7 days using calipers.
Tumour volumes (V) were calculated using the following
formula: V = A × B2/2 (A = largest diameter; B = smallest
diameter). Lungs were examined macroscopically and
microscopically for the presence of OS foci. For histologi-
cal and immunohistochemical evaluations, lung and sub-
cutaneous xenografts were collected and fixed in 10%
formalin and embedded in paraffin. Sections of 4 μm-
ticks were stained with Hematoxylin and Eosin and with
Masson's trichromic staining for conventional histology.
Patented blood vessels (vessels containing blood cells)
were counted on Masson's trichromic stained s.c.
xenograft sections from 3 different mice per group. The
mean of identified patented vessels+/-standard deviation
of 10 optical fields per slide were calculated. Lung foci
were counted under optical microscope at 40× magnifica-
tion on hematoxylin and eosin stained lung sections from
3 different mice per group. The surface occupied by OS
cells was calculated as a percentage of the whole optical
field.
Statistics
Xenograft volume and immunohistochemical quantifica-
tions were analyzed using Student's T test. Categorical var-
iables were analyzed using Fisher's exact test. P values <
0.05 were considered statistically significant.
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